| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 261 |
| Sex | Both Genders |
| Age Range | 65+ |
| Body Types | Average, Underweight |
Supplementation of Alpha-GPC at 400mg thrice daily (1,200mg daily) for 180 days in persons with mild to moderate Alzheimer's disease was able to improve symptoms as assessed by a multitude of rating scales including ADAS, MMSE, CDI, and GDS.
